KRYS · NASDAQ · Biotechnology

Krystal Biotech

Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.

$351.46
After-hours close+0.18 (+0.05%)
At close$351.28(−1.73%)
DateEstimateReportedSurprise
Nov 2026$1.91
Aug 2026$1.70$1.79+5.3%
May 2026$1.45$1.83+26.2%
Feb 2026$1.62$1.70+4.9%
Nov 2025$1.12$2.66+137.5%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Nov 2017
Sep 2017
Jun 2017
Dec 2016
Sep 2016
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 2, 2026$1.91$129.6M
Aug 3, 2026$1.70$1.79+5.3%$120.9M$119.2M−1.4%
May 4, 2026$1.45$1.83+26.2%$112.1M$116.4M+3.8%
Feb 17, 2026$1.62$1.70+4.9%$105.3M$107.1M+1.7%
Nov 3, 2025$1.12$2.66+137.5%$105.3M$97.8M−7.1%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 4, 2025
May 6, 2025
Feb 19, 2025
Nov 4, 2024
Aug 5, 2024
May 6, 2024
Feb 26, 2024
Nov 6, 2023
Aug 7, 2023
May 8, 2023
Feb 27, 2023
Nov 7, 2022
Aug 8, 2022
May 9, 2022
Feb 28, 2022
Nov 8, 2021
Aug 9, 2021
May 10, 2021
Mar 1, 2021
Nov 9, 2020
Aug 10, 2020
May 4, 2020
Mar 10, 2020
Nov 4, 2019
Aug 5, 2019
May 7, 2019
Mar 12, 2019
Nov 5, 2018
Aug 6, 2018
May 7, 2018
Mar 12, 2018
Nov 13, 2017
Sep 20, 2017
Jun 30, 2017
Dec 31, 2016
Sep 30, 2016